Mount Sinai Researchers Awarded $3.15 Million to Advance a Multidisciplinary Drug Development Platform for Hepatocellular Carcinoma

The National Cancer Institute has awarded Mount Sinai researchers $3.15 million in grant funding to assess the potential of a multidisciplinary drug development platform to identify new biological targets for precision-based therapeutics for hepatocellular carcinoma.